2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
Revenue of 2seventy bio, Inc. (TSVT)
Revenue in 2023 (TTM): $100.39 M
According to 2seventy bio, Inc.'s latest financial reports the company's current revenue (TTM) is $100.39 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of 2seventy bio, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $100.39 M | $83.47 M | $-206,418,000 | $-217,570,000 | $-217,570,000 |
| 2022 | $91.5 M | $65.28 M | $-251,375,000 | $-254,153,000 | $-254,144,013 |
| 2021 | $54.52 M | $41.93 M | $-297,159,000 | $-292,213,000 | $-276,214,000 |
| 2020 | $248.12 M | $242.73 M | $-131,449,999 | $-120,114,000 | $-138,170,000 |
| 2019 | $44.3 M | $41.32 M | $-329,186,000 | $-320,594,000 | $-323,341,000 |
| 2018 | $54.58 M | $53.69 M | $-187,082,000 | $-199,749,000 | $-199,749,000 |